Intriguingly, CPS1 displays tissue-specific oncogenicity: its overexpression in colorectal tumors of patients with a poor neoadjuvant chemoradiotherapy response is associated with reduced pathological complete remission rates and shortened progression-free survival [35], while hepatocellular carcinoma studies demonstrate that CPS1 deficiency enhances radiation resistance through c-Myc regulation [36]. This evidence concerns the gene CPS1 and colorectal neoplasm.